Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 12;13:272. doi: 10.1038/s41467-021-27945-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — A Schematic of cohorts dosed with pegadricase alone (Cohort A), single escalating doses of ImmTOR alone (Cohorts B–E), or single escalating doses of SEL-212 (Cohorts F–J, 0.03, 0.1, 0.15, or 0.3 mg/kg ImmTOR combined with a fixed dose of 0.4 mg/kg pegadricase). Cohorts B–E were double blinded and randomized to either placebo or study drug in a 2:5 rato, while Cohorts A and F–J were open-label. All cohorts consisted of 5 drug-treated patients, except for Cohort G, that contained 10 patients and Cohort J which contained 6 patients. In addition, Cohorts B–F each contained two patients that received placebo (vehicle). Patients in Cohorts F–I received an IV infusion of ImmTOR followed immediately by an IV infusion of pegadricase. Patients in Cohort J received an IV infusion of pegadricase followed 48 h later by an IV infusion of ImmTOR. B Serum uric acid levels over time. Each symbol represents sUA levels for an individual patient at various timepoints indicated and the lines indicate mean sUA levels for the cohort. The dotted black line represents 6 mg/dL sUA. Source data are provided as a Source Data file.